Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex

Elbert D. Glover, David P.L. Sachs, Maxine L. Stitzer, Stephen I. Rennard, William C. Wadland, Ovide F. Pomerleau, Robert T. Nowak, David M. Daughton, Penny N. Glover, John R. Hughes, Janet Gross

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


The objective was to evaluate the efficacy of nicotine polacrilex 4 mg for smoking cessation in highly nicotine-dependent cigarette smokers defined by an expired carbon monoxide level of ≥ 15 ppm and a FTQ score of ≥7. The design was a multicenter, double-blind, randomized, parallel, 6-week clinical trial. 563 highly nicotine-dependent cigarette smokers were randomized to one of three treatment interventions, (a) placebo, (b) 2 mg, or (c) 4 mg nicotine polacrilex. Overall, patients assigned to the 4 mg treatment group had a 39% abstinence rate, compared to 33% and 30% quit rate for the 2 mg and placebo groups respectively (p = .191). Results indicate that, in compliant Ss (those using ≥9 pieces of medication/day), 56% of Ss in the 4 mg treatment group were abstinent, compared to 33% and 33% respectively, in the 2 mg and placebo groups (p = .0016). It was concluded that 4 mg nicotine polacrilex is an effective aid to smoking cessation in compliant, highly-dependent smokers.

Original languageEnglish (US)
Pages (from-to)319-332
Number of pages14
JournalAmerican Journal of Health Behavior
Issue number5
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Health(social science)
  • Social Psychology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex'. Together they form a unique fingerprint.

Cite this